Studies such as the LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown reductions in major adverse cardiovascular events, including heart attack and stroke, in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk
This "diet break" allows hormonal markers related to muscle preservation (testosterone, IGF-1, thyroid hormones) to recover from the sustained deficit
Significant weight loss from tirzepatide may reduce levothyroxine requirements in some patients, necessitating TSH monitoring at baseline, after substantial weight loss, and every 6-12 months once stable
AHK-Cu is often highlighted in hair systems for its role in supporting hair density and scalp health, while GHK-Cu is more commonly associated with skin repair and rejuvenation
Fat loss improved by up to 27% vs semaglutide alone
The effective use of LCPUFAs and antioxidants should be viewed not as isolated strategies but as integrated nutritional interventions